LNCD(SH:600739) Xin Lang Cai Jing·2025-10-30 17:03Core Viewpoint - Liaoning Chengda has established itself as a comprehensive enterprise with significant investment value, operating in various sectors including pharmaceuticals, financial investments, supply chain services, and energy development [1] Group 1: Business Performance - In Q3 2025, Liaoning Chengda achieved a revenue of 8.114 billion, ranking first among 14 companies in the industry [2] - The company's net profit for the same period was 1.453 billion, also leading the industry [2] - The main business segments include domestic and foreign trade (4.634 billion, 86.64%), biopharmaceuticals (707 million, 13.22%), and others (7.47 million, 0.14%) [2] Group 2: Financial Ratios - As of Q3 2025, Liaoning Chengda's debt-to-asset ratio was 31.75%, higher than the industry average of 27.82% [3] - The gross profit margin for the same period was 12.49%, which is below the industry average of 63.72% [3] Group 3: Executive Compensation - The chairman, Xu Biao, received a salary of 80,000, unchanged from the previous year [4] - The president, Zhang Shanwei, earned 1.5415 million, an increase of 23,200 from the previous year [4] Group 4: Shareholder Information - As of September 30, 2025, the number of A-share shareholders decreased by 8.64% to 60,300 [5] - The average number of circulating A-shares held per shareholder increased by 9.45% to 25,400 [5] - Notable shareholders include Southern CSI 500 ETF and Hong Kong Central Clearing Limited, both of which saw a reduction in their holdings [5]